Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy

Xiaoxin Yan , Jinhu Liu , Jie Liu , Suyun Wei , Ruixin Li , Weiwei Mu , Na Zhang , Yongjun Liu

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101119

PDF (7149KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101119 DOI: 10.1016/j.ajps.2026.101119
Review Article
research-article
Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy
Author information +
History +
PDF (7149KB)

Abstract

Tumors pose a serious threat to human life and health. In recent years, gene therapy against tumors has garnered considerable attention. Small interfering RNAs (siRNAs), an important class of nucleic acid drugs, can silence the mRNAs of tumor-associated genes with high specificity through RNA interference (RNAi), inhibiting tumor-related signaling pathways or protein expression and thereby exerting anti-tumor effects. However, anti-tumor siRNA drugs are currently in the clinical research stage, and none of these drugs have been approved for marketing, mainly because of the challenges in terms of safety, efficacy and targeted delivery. Nano-delivery systems can enhance siRNA stability and improve siRNA pharmacokinetics and biodistribution, while increasing their uptake by target cells to achieve precise delivery and controlled release, thereby serving as a promising solution to overcome the challenges of siRNA drug application. This review summarizes the existing research on the nano-delivery systems currently available to help siRNAs achieve organ-targeted delivery and enhance the anti-tumor efficacy of siRNAs, discussing the characteristics of siRNA action and the unique advantages of different types of nano-delivery systems. The aim was to provide novel ideas for the design and optimization of siRNA-based drug delivery and the development of novel anti-tumor formulations to promote the clinical translation and application of siRNA drugs.

Keywords

siRNA / Nano-delivery system / Tumor therapy / Organ-targeted delivery

Cite this article

Download citation ▾
Xiaoxin Yan, Jinhu Liu, Jie Liu, Suyun Wei, Ruixin Li, Weiwei Mu, Na Zhang, Yongjun Liu. Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101119 DOI:10.1016/j.ajps.2026.101119

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023; 20: 338-49.

[2]

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health 2023; 11: e197-206.

[3]

Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79: 516-37.

[4]

Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, et al. A new age of precision gene therapy. Lancet 2024; 403: 568-82.

[5]

Butterfield GL, Reisman SJ, Iglesias N, Gersbach CA. Gene regulation technologies for gene and cell therapy. Mol Ther 2025; 33: 2104-22.

[6]

Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature 2009; 457: 396-404.

[7]

Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-6.

[8]

Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, et al. Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer. Int J Biol Sci 2023; 19: 3360-82.

[9]

Xie X, Yu T, Li X, Zhang N, Foster LJ, Peng C, et al. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduct Target Ther 2023; 8: 335.

[10]

Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 2019; 18: 421-46.

[11]

Jadhav V, Vaishnaw A, Fitzgerald K, Maier MA. RNA interference in the era of nucleic acid therapeutics. Nat Biotechnol 2024; 42: 394-405.

[12]

Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev 2022; 182: 114113.

[13]

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther 2020; 5: 101.

[14]

Paul S, Gray D, Caswell J, Brooks J, Ye W, Moody TS, et al. Convergent biocatalytic mediated synthesis of siRNA. ACS Chem Biol 2023; 18: 2183-7.

[15]

Cao X, Cai Z, Zhang J, Zhao F. Engineering circular RNA medicines. Nat Rev Bioeng 2024; 3: 270-87.

[16]

Wang D, Liu B, Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics. Cell 2023; 186: 1755-71.

[17]

Zhang Y, Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun 2022; 13: 2669.

[18]

Cron RQ, Goyal G, Chatham WW. Cytokine storm syndrome. Annu Rev Med 2023; 74: 321-37.

[19]

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-95.

[20]

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255-73.

[21]

Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics: challenges and potential solutions. Nat Rev Drug Discov 2021; 20: 629-51.

[22]

Nedorezova DD, Dubovichenko MV, Belyaeva EP, Grigorieva ED, Peresadina AV, Kolpashchikov DM. Specificity of oligonucleotide gene therapy (OGT) agents. Theranostics 2022; 12: 7132-57.

[23]

Iversen F, Yang C, Dagnæs-Hansen F, Schaffert DH, Kjems J, Gao S. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 2013; 3: 201-9.

[24]

Gao S, Dagnaes-Hansen F, Nielsen EJB, Wengel J, Besenbacher F, Howard KA, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009; 17: 1225-33.

[25]

Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 2018; 16: 71.

[26]

Xia Y, Fu S, Ma Q, Liu Y, Zhang N. Application of nano-delivery systems in lymph nodes for tumor immunotherapy. Nano-Micro Lett 2023; 15: 145.

[27]

Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers 2022; 2: 24.

[28]

Huang X, He T, Liang X, Xiang Z, Liu C, Zhou S, et al. Advances and applications of nanoparticles in cancer therapy. MedComm Oncol 2024; 3: e67.

[29]

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.

[30]

Wianny F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol 2000; 2: 70-5.

[31]

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.

[32]

Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.

[33]

Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305: 1437-41.

[34]

Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res 2019; 52: 2435-44.

[35]

Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-40.

[36]

Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-6.

[37]

Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev 2005; 19: 517-29.

[38]

Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.

[39]

Yu J, Zhang X, Cai C, Zhou T, Chen Q. Small RNA and toll-like receptor interactions: origins and disease mechanisms. Trends Biochem Sci 2025; 50: 385-401.

[40]

Shimizu T. RNA recognition in toll-like receptor signaling. Curr Opin Struct Biol 2024; 88: 102913.

[41]

Ghafouri-Fard S, Abak A, Shoorei H, Talebi SF, Mohaqiq M, Sarabi P, et al. Interaction between non-coding RNAs and toll-like receptors. Biomed Pharmacother 2021; 140: 111784.

[42]

Lee CC, Avalos AM, Ploegh HL. Accessory molecules for toll-like receptors and their function. Nat Rev Immunol 2012; 12: 168-79.

[43]

Lind NA, Rael VE, Pestal K, Liu B, Barton GM. Regulation of the nucleic acid-sensing toll-like receptors. Nat Rev Immunol 2022; 22: 224-35.

[44]

Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell 2020; 180: 1044-66.

[45]

Jin M, Fang J, Wang J, Shao X, Xu S, Liu P, et al. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacol Sin 2023; 44: 2358-75.

[46]

Colonna M, Trinchieri G, Liu Y-J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-26.

[47]

Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-7.

[48]

Li X, Hu H, Wang H, Liu J, Jiang W, Zhou F, et al. DNA nanotechnology-based strategies for minimising hybridisation-dependent off-target effects in oligonucleotide therapies. Mater Horiz 2025; 12: 1388-412.

[49]

Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199-204.

[50]

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 2020; 19: 673-94.

[51]

Richter M, Viel JA, Kotikam V, Gajula PK, Coyle L, Pal C, et al. Amide modifications in the seed region of the guide strand improve the on-target specificity of short interfering RNA. ACS Chem Biol 2023; 18: 7-11.

[52]

Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun 2018; 9: 723.

[53]

Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J, Burge CB. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 2007; 13: 1894-1910.

[54]

Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjær N, Odadzic D, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010; 38: 5761-73.

[55]

Song X, Wang X, Ma Y, Liang Z, Yang Z, Cao H. Site-specific modification using the 2’-methoxyethyl group improves the specificity and activity of siRNAs. Mol Ther Nucleic Acids 2017; 9: 242-50.

[56]

Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 2006; 12: 1197-205.

[57]

Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol 2021; 77: 1182-93.

[58]

Ragni MV, Georgiev P, Desmond Creagh M, Lissitchkov TJ, Austin SK, Hay CRM, et al. The role of antithrombin lowering in patients with hemophilia: hemostatic control pre- and post-fitusiran dosing interruption. Blood 2018; 132: 2477.

[59]

Pipe SW, Kavakli K, Matsushita T, Tran H, Zulfikar B, Menapace L, et al. Reduced doses of factor concentrates and bypassing agents to treat breakthrough bleeds in patients with hemophilia A and B on fitusiran antithrombin-based dosing regimen: ATLAS-OLE. Blood 2024; 144: 128.

[60]

Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 2009; 17: 725-32.

[61]

Zhang J, Zheng J, Lu C, Du Q, Liang Z, Xi Z. Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects. Chembiochem 2012; 13: 1940-5.

[62]

Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21: 492-7.

[63]

Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You C-W, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023; 401: 1427-37.

[64]

Trusolino L, Bertotti A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. Cancer Discov 2012; 2: 876-80.

[65]

Guo L, Lin J, Ren Q, Sun H, Wu Y, Ge H, et al. Enhanced activities of OCT4 and SOX2 promote epigenetic reprogramming by shortening G1 phase. Adv Sci (Weinh) 2025: e15528.

[66]

Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res 2019; 38: 53.

[67]

Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 2015; 14: 843-56.

[68]

Jörgensen AM, Wibel R, Bernkop-Schnürch A. Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients. Small 2023; 19: e2206968.

[69]

Liu Y, Zhu S, Gu Z, Chen C, Zhao Y. Toxicity of manufactured nanomaterials. Particuology 2022; 69: 31-48.

[70]

Mohammapdour R, Ghandehari H. Mechanisms of immune response to inorganic nanoparticles and their degradation products. Adv Drug Deliv Rev 2022; 180: 114022.

[71]

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.

[72]

Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 2018; 9: 1410.

[73]

Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol 2018; 13: 1100-8.

[74]

Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 2017; 17: 181.

[75]

Lamb YN. Inclisiran: first approval. Drugs 2021; 81: 389-95.

[76]

Scott LJ, Keam SJ. Lumasiran: first approval. Drugs 2021; 81: 277-82.

[77]

Tai W. Chemical modulation of siRNA lipophilicity for efficient delivery. J Control Release 2019; 307: 98-107.

[78]

McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab Dispos 2022; 50: 781-97.

[79]

Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.

[80]

Zheng M, Tao W, Zou Y, Farokhzad OC, Shi B. Nanotechnology-based strategies for siRNA brain delivery for disease therapy. Trends Biotechnol 2018; 36: 562-75.

[81]

Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov 2021; 20: 362-83.

[82]

Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther 2023; 8: 217.

[83]

Wang C, Xu J, Zhang Y, Nie G. Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy. J Control Release 2023; 362: 647-66.

[84]

Steeg PS. The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol 2021; 18: 696-714.

[85]

Cox TR. The matrix in cancer. Nat Rev Cancer 2021; 21: 217-38.

[86]

Valkenburg KC, De Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 2018; 15: 366-81.

[87]

Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 2017; 35: 222-9.

[88]

Qiu C, Xia F, Zhang J, Shi Q, Meng Y, Wang C, et al. Advanced strategies for overcoming endosomal/lysosomal barrier in nanodrug delivery. Research (Wash DC) 2023; 6: 0148.

[89]

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 2017; 35: 238-48.

[90]

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017; 376: 41-51.

[91]

Khvorova A. Oligonucleotide therapeutics-a new class of cholesterol-lowering drugs. N Engl J Med 2017; 376: 4-7.

[92]

Patutina OA, Gaponova Miroshnichenko SK, Sen’kova AV, Savin IA, Gladkikh DV, Burakova EA, et al. Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency . Proc Natl Acad Sci USA 2020; 117: 32370-9.

[93]

Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov 2024; 23: 341-64.

[94]

Gangopadhyay S, Gore KR. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biol 2022; 19: 452-67.

[95]

Crooke ST, Wang S, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 2017; 35: 230-7.

[96]

Migawa MT, Shen W, Wan WB, Vasquez G, Oestergaard ME, Low A, et al. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res 2019; 47: 5465-79.

[97]

Crooke ST, Vickers TA, Liang XH. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res 2020; 48: 5235-53.

[98]

Prakash TP, Lima WF, Murray HM, Li W, Kinberger GA, Chappell AE, et al. Identification of metabolically stable 5’-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Res 2015; 43: 2993-3011.

[99]

Haraszti RA, Roux L, Coles AH, Turanov AA, Alterman JF, Echeverria D, et al. 5 ΄-vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo . Nucleic Acids Res 2017; 45: 7581-92.

[100]

Kaushal A. Innate immune regulations and various siRNA modalities. Drug Deliv Transl Res 2023; 13: 2704-18.

[101]

Yamada K, Hildebrand S, Davis SM, Miller R, Conroy F, Sapp E, et al. Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity. Nucleic Acids Res 2021; 49: 12069-88.

[102]

Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Karikó K. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 2011; 39: 9329-38.

[103]

Sahoo A, Das G, Ghosh A, Shivappa Bagale S, Kumar Choudhary N, Harikrishna S, et al. N3-methyluridine and 2′-O-alkyl/2′-fluoro-N3-methyluridine functionalized nucleic acids improve nuclease resistance while maintaining duplex geometry . Bioorg Med Chem 2024; 100: 117616.

[104]

Feng P, Chen W. iRNA-m5U: a sequence based predictor for identifying 5-methyluridine modification sites in Saccharomyces cerevisiae. Methods 2022; 203: 28-31.

[105]

Rydzik AM, Gottschling D, Simon E, Skronska-Wasek W, Rippmann JF, Riether D. Epigenetic modification 6-methyladenosine can impact the potency and specificity of siRNA. Chembiochem 2021; 22: 491-5.

[106]

Li Q, Dong M, Chen P. Advances in structural-guided modifications of siRNA. Bioorg Med Chem 2024; 110: 117825.

[107]

Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov 2020; 19: 839-59.

[108]

Sun X, Setrerrahmane S, Li C, Hu J, Xu H. Nucleic acid drugs: recent progress and future perspectives. Signal Transduct Target Ther 2024;9:316.

[109]

Vicentini Q, Hekman D, Bhatt D, Stulz R, Dezfouli M, Gennemark P, et al. Multimeric conjugates using engineered peptide scaffolds for efficient siRNA delivery. Bioconjug Chem 2025; 36: 1299-310.

[110]

Schlegel MK, Janas MM, Jiang Y, Barry JD, Davis W, Agarwal S, et al. From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization. Nucleic Acids Res 2022; 50: 6656-70.

[111]

Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther 2020; 28: 1759-71.

[112]

Guo S, Zhang M, Huang Y. Three ‘E’ challenges for siRNA drug development. Trends Mol Med 2024; 30: 13-24.

[113]

Shi Y, Zhen X, Zhang Y, Li Y, Koo S, Saiding Q, et al. Chemically modified platforms for better RNA therapeutics. Chem Rev 2024; 124: 929-1033.

[114]

Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov 2024; 23: 709-22.

[115]

Huang X, Ma Y, Ma G, Xia Y. Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies. Research (Wash DC) 2024; 7: 0370.

[116]

El Moukhtari SH, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-León A, Prosper F, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release 2023; 361: 130-46.

[117]

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther 2024; 32: 284-312.

[118]

Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev 2022; 188: 114416.

[119]

Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci USA 2024; 121: e2307800120.

[120]

Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013; 31: 653-8.

[121]

Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res 2022; 55: 2-12.

[122]

Jeong M, Lee Y, Park J, Jung H, Lee H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications . Adv Drug Deliv Rev 2023; 200: 114990.

[123]

Hemmrich E, McNeil S. Active ingredient vs excipient debate for nanomedicines. Nat Nanotechnol 2023; 18: 692-5.

[124]

Ralvenius WT, Andresen JL, Huston MM, Penney J, Bonner JM, Fenton OS, et al. Nanoparticle-mediated delivery of anti-PU.1 siRNA via localized intracisternal administration reduces neuroinflammation. Adv Mater 2024; 36: 2309225.

[125]

Huang Y, Zheng S, Guo Z, de Mollerat du Jeu X, Liang XJ, Yang Z, et al. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. Signal Transduct Target Ther 2022; 7: 1-14.

[126]

Kim KH, Bhujel R, Maharjan R, Lee JC, Jung HS, Kim HJ, et al. Biophysical characterization of siRNA-loaded lipid nanoparticles with different PEG content in an aqueous system. Eur J Pharm Biopharm 2023; 190: 150-60.

[127]

Berger M, Toussaint F, Ben Djemaa S, Maquoi E, Pendeville H, Evrard B, et al. Poly(N-methyl-N-vinylacetamide): a strong alternative to PEG for lipid-based nanocarriers delivering siRNA. Adv Healthc Mater 2023; 13: e2302712.

[128]

Song H, Hart SL, Du Z. Assembly strategy of liposome and polymer systems for siRNA delivery. Int J Pharm 2021; 592: 120033.

[129]

Yildiz SN, Entezari M, Paskeh MDA, Mirzaei S, Kalbasi A, Zabolian A, et al. Nanoliposomes as nonviral vectors in cancer gene therapy. MedComm (2020) 2024; 5: e583.

[130]

Wei P-S, Thota N, John G, Chang E, Lee S, Wang Y, et al. Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies. J Control Release 2024; 375: 366-88.

[131]

Zhao Y, Qin J, Yu D, Liu Y, Song D, Tian K, et al. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2024; 19: 1869-79.

[132]

Shin JH, Shin DH, Kim JS. Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells. Asian J Pharm Sci 2020; 15: 472-81.

[133]

Li Y, Tan X, Liu X, Liu L, Fang Y, Rao R, et al. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with bcl-2 siRNA-corona for dual suppression of drug resistance. Asian J Pharm Sci 2020; 15: 646-60.

[134]

Narmani A, Jafari SM. Chitosan-based nanodelivery systems for cancer therapy: recent advances. Carbohydr Polym 2021; 272: 118464.

[135]

Mao L, Ma P, Luo X, Cheng H, Wang Z, Ye E, et al. Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy. ACS Nano 2023; 17: 9826-49.

[136]

Yang W, Wang N, Yang J, Liu C, Ma S, Wang X, et al. A multifunctional ‘golden cicada’ nanoplatform breaks the thermoresistance barrier to launch cascade augmented synergistic effects of photothermal/gene therapy. J Nanobiotechnol 2023; 21: 228.

[137]

Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev 2024; 124: 5505-616.

[138]

Huang R, Du H, Cheng L, Zhang P, Meng F, Zhong Z. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer. Acta Biomater 2023; 168: 529-39.

[139]

Song P, Wang B, Pan Q, Jiang T, Chen X, Zhang M, et al. GE11-modified carboxymethyl chitosan micelles to deliver DOX ·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor. Carbohydr Polym 2023; 312: 120837.

[140]

Zhou Z, Feng Y, Jiang M, Yao Z, Wang J, Pan F, et al. Ionizable polymeric micelles (IPMs) for efficient siRNA delivery. Nat Commun 2025; 16: 360.

[141]

Amaldoss MJN, Yang J-L, Koshy P, Unnikrishnan A, Sorrell CC. Inorganic nanoparticle-based advanced cancer therapies: promising combination strategies. Drug Discov Today 2022; 27: 103386.

[142]

Wang L, Yan Y. A review of pH-responsive organic-inorganic hybrid nanoparticles for RNAi-based therapeutics. Macromol Biosci 2021; 21: e2100183.

[143]

Kandasamy G, Maity D. Inorganic nanocarriers for siRNA delivery for cancer treatments. Biomed Mater 2024; 19: 022001.

[144]

Chen S, He Y, Huang X, Shen Y, Zou Q, Yang G, et al. Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer. J Nanobiotechnol 2024; 22: 348.

[145]

Rahimkhoei V, Alzaidy AH, Abed MJ, Rashki S, Salavati-Niasari M. Advances in inorganic nanoparticles-based drug delivery in targeted breast cancer theranostics. Adv Colloid Interface Sci 2024; 329: 103204.

[146]

Bakhtiar A, Chowdhury EH. PH-responsive strontium nanoparticles for targeted gene therapy against mammary carcinoma cells. Asian J Pharm Sci 2021; 16: 236-52.

[147]

Zhao Y, Zhao T, Cao Y, Sun J, Zhou Q, Chen H, et al. Temperature-sensitive lipid-coated carbon nanotubes for synergistic photothermal therapy and gene therapy. ACS Nano 2021; 15: 6517-29.

[148]

Lu J, Song J, Zhang P, Huang Y, Lu X, Dai H, et al. Biomineralized polydopamine nanoparticle-based sodium alginate hydrogels for delivery of anti-serine/threonine protein kinase B-rapidly accelerated fibrosarcoma siRNA for metastatic melanoma therapy. ACS Nano 2023; 17: 18318-18331.

[149]

Lu Y, Gu F, Ma Y, Li R, Luo Y, Da X, et al. Simultaneous delivery of doxorubicin and EZH2-targeting siRNA by vortex magnetic nanorods synergistically improved anti-tumor efficacy in triple-negative breast cancer. Small 2023; 19: 2301307.

[150]

Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, et al. A PD-L1 siRNA-loaded boron nanoparticle for targeted cancer radiotherapy and immunotherapy. Adv Mater 2025; 37: 2419418.

[151]

Li L, Zhang M, Li J, Liu T, Bao Q, Li X, et al. Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy. Nat Commun 2023; 14: 5111.

[152]

He Y, Zhang S, She Y, Liu Z, Zhu Y, Cheng Q, et al. Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy. Exploration 2024; 4: 20230164.

[153]

Cecchin R, Troyer Z, Witwer K, Morris KV. Extracellular vesicles: the next generation in gene therapy delivery. Mol Ther 2023; 31: 1225-30.

[154]

Huang X, Guo H, Wang L, Zhang Z, Zhang W. Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy. Drug Discov Today 2023; 28: 103514.

[155]

Li J, Zeng H, Li L, Yang Q, He L, Dong M. Advanced generation therapeutics: biomimetic nanodelivery system for tumor immunotherapy. ACS Nano 2023; 17: 24593-618.

[156]

Zhou Y, Liang Q, Wu X, Duan S, Ge C, Ye H, et al. siRNA delivery against myocardial ischemia reperfusion injury mediated by reversibly camouflaged biomimetic nanocomplexes. Adv Mater 2023; 35: 2210691.

[157]

Zhuo Y, Luo Z, Zhu Z, Wang J, Li X, Zhang Z, et al. Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes. Nat Nanotechnol 2024; 19: 1858-68.

[158]

Chen Y, Li K, Jiao M, Huang Y, Zhang Z, Xue L, et al. Reprogrammed siTNF α/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy . Acta Pharm Sin B 2023; 13: 787-803.

[159]

Wang Y, Bruggeman KF, Franks S, Gautam V, Hodgetts SI, Harvey AR, et al. Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater 2021; 10: 2001238.

[160]

Motamedi H, Ari MM, Alvandi A. Principle application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review. Front Microbiol 2024; 15: 1393646.

[161]

Johnston CD, Wargo JA. Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol 2024; 45: 931-3.

[162]

Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu SI, Byrne BJ, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. Lancet Child Adolesc Health 2017; 1: 265-73.

[163]

Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia a randomized clinical trial. JAMA Ophthalmol 2019; 137: 1247-54.

[164]

Rittié L, Athanasopoulos T, Calero-Garcia M, Davies ML, Dow DJ, Howe SJ, et al. The landscape of early clinical gene therapies outside of oncology. Mol Ther 2019; 27: 1706-17.

[165]

Broekhoff TF, Sweegers CCG, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health 2021; 24: 759-69.

[166]

Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA 2017; 318: 1861-2.

[167]

Qiu CJ, Hu LY, Yang J, Cao J, Pei B, Dai R, et al. A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth. Int J Biol Macromol 2024; 276: 134025.

[168]

Zhu D, Pan W, Li H, Hua J, Zhang C, Zhao K. Innovative applications of bacteria and their derivatives in targeted tumor therapy. ACS Nano 2025; 19: 5077-109.

[169]

Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A. Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsyst Nanoeng 2024; 10: 113.

[170]

Sun D, Li Y, Yin X, Fan Y, Liu J, Wang Y, et al. Utilizing engineered bacteria as “cell factories” in vivo for intracellular RNA-loaded outer membrane vesicles’ self-assembly in tumor treatment . ACS Nano 2024; 18: 35296-309.

[171]

Tang S, Tang D, Zhou H, Li Y, Zhou D, Peng X, et al. Bacterial outer membrane vesicle nanorobot. Proc Natl Acad Sci USA 2024; 121: e2403460121.

[172]

Chen Y, Zhou Q, Yuan F. Emerging applications of catalytically inactive CRISPR-Cas13 system in mRNA engineering. Biomed Eng Commun 2022; 1: 2.

[173]

Wannier TM, Ciaccia PN, Ellington AD, Filsinger GT, Isaacs FJ, Javanmardi K, et al. Recombineering and MAGE. Nat Rev Methods Primers 2021; 1: 7.

[174]

Suzuki Y, Katsurada Y, Hyodo K. Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles. Mol Pharm 2023; 20: 4883-92.

[175]

Lv K, Yu Z, Wang J, Li N, Wang A, Xue T, et al. Discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery. Adv Sci (Weinh) 2024; 11: 2404684.

[176]

Gomes Souza L, Antonio Sousa-Junior A, Alves Santana Cintra B, Vieira Dos Anjos JL, Leite Nascimento T, Palmerston Mendes L, et al. Pre-clinical safety of topically administered sunitinib-loaded lipid and polymeric nanocarriers targeting corneal neovascularization. Int J Pharm 2023; 635: 122682.

[177]

Zhang Y, Chen J, Shi L, Ma F. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. Mater Horiz 2023; 10: 361-92.

[178]

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270: 834-41.

[179]

Unterweger H, Janko C, Folk T, Cicha I, Kovács N, Gyebnár G, et al. Comparative in vitro and in vivo evaluation of different iron oxide-based contrast agents to promote clinical translation in compliance with patient safety . Int J Nanomed 2023; 18: 2071-86.

[180]

Oh JY, Villaseñor KE, Kian AC, Cormode DP. Advances in ultrasmall inorganic nanoparticles for nanomedicine: from diagnosis to therapeutics. ACS Appl Mater Interfaces 2025; 17: 28982-9001.

[181]

Zhang JA, Feng K, Shen W-T, Gao W, Zhang L. Research advances of cellular nanoparticles as multiplex countermeasures. ACS Nano 2024; 18: 30211-23.

[182]

Kondo T, Bourassa FXP, Achar S, DuSold J, Céspedes PF, Ando M, et al. Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. Cell 2025; 188: 2372-2389.e35.

[183]

Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol 2024; 21: 569-89.

[184]

Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther 2024; 9: 78.

[185]

Simonsen JB. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies-challenges and opportunities. J Control Release 2024; 370: 763-72.

[186]

Han X, Gong N, Xue L, Billingsley MM, El-Mayta R, Shepherd SJ, et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat Commun 2023; 14: 75.

[187]

Zhou J-E, Sun L, Liu L, Jia Y, Han Y, Shao J, et al. Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. J Control Release 2022; 343: 175-86.

[188]

Alshaikh RA, Waeber C, Ryan KB. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Adv Drug Deliv Rev 2022; 187: 114342.

[189]

Guo S, Li C, Wang C, Cao X, Liu X, Liang XJ, et al. pH-responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy. Acta Pharm Sin B 2024; 14: 781-94.

[190]

Agarwal P, Rupenthal ID. Non-aqueous formulations in topical ocular drug delivery - a paradigm shift? Adv Drug Deliv Rev 2023; 198: 114867.

[191]

Baran-Rachwalska P, Torabi-Pour N, Sutera FM, Ahmed M, Thomas K, Nesbit MA, et al. Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. J Control Release 2020; 326: 192-202.

[192]

Nance E, Pun SH, Saigal R, Sellers DL. Drug delivery to the central nervous system. Nat Rev Mater 2021; 7: 314-31.

[193]

Wu H, Wang Y, Ren Z, Cong H, Shen Y, Yu B. The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy. Chin Chem Lett 2025; 36: 109996.

[194]

Tang L, Zhang R, Wang Y, Liu M, Hu D, Wang Y, et al. A blood-brain barrier- and blood-brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy. J Control Release 2024; 369: 642-57.

[195]

Chung S, Sugimoto Y, Huang J, Zhang M. Iron oxide nanoparticles decorated with functional peptides for a targeted siRNA delivery to glioma cells. ACS Appl Mater Interfaces 2023; 15: 106-19.

[196]

Cui Y, Guo Y, Kong L, Shi J, Liu P, Li R, et al. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact Mater 2022; 10: 207-21.

[197]

Zhou D, Wei Y, Sheng S, Wang M, Lv J, Zhao B, et al. MMP13-targeted siRNA-loaded micelles for diagnosis and treatment of posttraumatic osteoarthritis. Bioact Mater 2024; 37: 378-92.

[198]

Bedingfield SK, Colazo JM, Yu F, Liu DD, Jackson MA, Himmel LE, et al. Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat Biomed Eng 2021; 5: 1069-83.

[199]

Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 2023; 18: 265-91.

[200]

Kim M, Song ES, Chen JC, Chatterjee S, Sun Y, Lee SM, et al. Dual SORT LNPs for multi-organ base editing. Nat Biotechnol 2025. doi: 10.1038/s41587-025-02675-z.

[201]

Vaidya A, Moore S, Chatterjee S, Guerrero E, Kim M, Farbiak L, et al. Expanding RNAi to kidneys, lungs, and spleen via selective organ targeting (SORT) siRNA lipid nanoparticles. Adv Mater 2024; 36: 2313791.

[202]

Sun Y, Chatterjee S, Lian X, Traylor Z, Sattiraju SR, Xiao Y, et al. In vivo editing of lung stem cells for durable gene correction in mice . Science 2024; 384: 1196-202.

[203]

Li J, Wang N, Zhang W, Peng C, Zhang X, Li M, et al. Zwitterionic polymer lipid nanoparticles enabling selective organ targeting delivery of small interfering RNA for the treatment of hepatic and pulmonary inflammation. Small 2025; 21: 2407041.

[204]

Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell 2023; 186: 1564-79.

[205]

Karras P, Black JRM, McGranahan N, Marine JC. Decoding the interplay between genetic and non-genetic drivers of metastasis. Nature 2024; 629: 543-54.

[206]

de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 2023; 41: 374-403.

[207]

Li T, Wang Y, Chen X, Cui H, Zhang L, Liu J, et al. Direct cytosolic delivery of siRNA conjugates: a paradigm in antiangiogenic therapy for choroidal neovascularization. ACS Nano 2025; 19: 11249-62.

[208]

Kwak G, Jo SD, Kim D, Kim H, Kim MG, Kim K, et al. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. J Control Release 2017; 267: 203-13.

[209]

Yang M, Qin C, Tao L, Cheng G, Li J, Lv F, et al. Synchronous targeted delivery of TGF- β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment . Biomaterials 2023; 301: 122253.

[210]

Jiang J, Lu Y, Chu J, Zhang X, Xu C, Liu S, et al. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases. J Nanobiotechnol 2024; 22: 159.

[211]

Yi Y, Yu M, Feng C, Hao H, Zeng W, Lin C, et al. Transforming “cold” tumors into “hot” ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy. Matter 2022; 5: 2285-305.

[212]

Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 2023; 8: 198.

[213]

Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer 2024; 24: 655-75.

[214]

Li B, Niu H, Zhao X, Huang X, Ding Y, Dang K, et al. Targeted anti-cancer therapy: co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy. Asian J Pharm Sci 2024; 19: 100891.

[215]

Chen H, Li Y, Li H, Chen X, Fu H, Mao D, et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature 2024; 631: 663-9.

[216]

Song H, Chen L, Pan X, Shen Y, Ye M, Wang G, et al. Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer Cell 2025; 43: 503-518.e10.

[217]

Chen C, Yu M, Li Q, Zhou Y, Zhang M, Cai S, et al. Programmable tetrahedral DNA-RNA nanocages woven with stimuli-responsive siRNA for enhancing therapeutic efficacy of multidrug-resistant tumors. Adv Sci (Weinh) 2024; 11: 2404112.

[218]

Liu H, Ma D, Chen J, Ye L, Li Y, Xie Y, et al. A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Res 2022; 15: 6306-14.

[219]

Xiong L, Chen S, Li S, He D, Wang Y, Zhang Q, et al. ATP-responsive tumor targeted lipid nanoparticle for enhanced siRNA delivery and improved treatment efficacy in melanoma. J Control Release 2025; 382: 113622.

[220]

You S, Li S, Zeng L, Song J, Li Z, Li W, et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer Cell 2024; 42: 1415-1433.e12.

[221]

Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 2023; 41: 421-33.

[222]

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541-50.

[223]

Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer 2021; 21: 298-312.

[224]

Xu X, Li S, Yu W, Yao S, Fan H, Guo Z. Activation of RIG-I/MDA5 signaling and inhibition of CD47-sirp α checkpoint with a dual siRNA-assembled nanoadjuvant for robust cancer immunotherapy . Angew Chem Int Ed Engl 2024; 63: e202318544.

[225]

Wang X, Yan Y, Guo X, Lu A, Jiang L, Zhu Y, et al. Enhanced tumor immunotherapy by triple amplification effects of nanomedicine on the STING signaling pathway in dendritic cells. Adv Healthc Mater 2025; 14: 2403143.

[226]

Wang X, Dong M, Yang J, Gong Y, Huang J, Yang Q, et al. Copackaging doxorubicin and PD-L1 siRNA in dual-responsive covalent organic frameworks for synergistic cancer chemoimmunotherapy. Adv Funct Mater 2024; 34: 2408846.

[227]

Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol 2023; 79: 1185-200.

[228]

Guo X, Yang Z, Guo Z, Lai H, Meng H, Meng M, et al. A polymeric mRNA vaccine featuring enhanced site-specific mRNA delivery and inherent STING-stimulating performance for tumor immunotherapy. Adv Mater 2025; 37: 2410998.

[229]

Qdaisat S, Wummer B, Stover BD, Zhang D, McGuiness J, Weidert F, et al. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nat Biomed Eng 2025: 1-16.

[230]

Wang B, Tang M, Chen Q, Ho W, Teng Y, Xiong X, et al. Delivery of mRNA encoding interleukin-12 and a stimulator of interferon genes agonist potentiates antitumor efficacy through reversing T cell exhaustion. ACS Nano 2024; 18: 15499-516.

[231]

Hamilton AG, Swingle KL, Joseph RA, Mai D, Gong N, Billingsley MM, et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering. Adv Healthc Mater 2023; 12: 2301515.

[232]

Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther 2024; 9: 150.

[233]

Kwak G, Jo SD, Kim D, Kim H, Kim MG, Kim K, et al. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. J Control Release 2017; 267: 203-13.

[234]

Zheng M, Yan C, Yang Q, Zhu F, Du Q, Xia X, et al. Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy. Chem Phys Mater 2022; 1: 203-10.

[235]

Huang J, Zheng C, Xiao H, Huang H, Wang Y, Lin M, et al. A polymer-calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy. J Control Release 2021; 340: 259-70.

[236]

Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy . Nat Nanotechnol 2023; 18: 193-204.

[237]

Yan J, Yu H, Liu C, Li B, Wei D, He B, et al. Low-temperature photothermal-chemotherapy enhancing tumor immunotherapy by tetrahedral framework nucleic acids nanogels based drug delivery system. Chem Eng J 2024; 481: 148616.

[238]

He S, Huang Y, Liu J, Liu H, Chen Y, Zou T, et al. A metformin-based multifunctional nanoplatform as a DNA damage amplifier for maximized radio-immunotherapy to overcome radiotherapy resistance. ACS Nano 2025; 19: 14848-64.

[239]

Shen H, Jin J, Yu N, Liu T, Nie Y, Wan Z, et al. PRKCSH enhances colorectal cancer radioresistance via IRE1 α/XBP1s-mediated DNA repair . Cell Death Dis 2025; 16: 258.

[240]

Wang Y, Wang H, Song Y, Lv M, Mao Y, Song H, et al. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation. J Nanobiotechnol 2022; 20: 96.

[241]

Shi M, Zhang J, Wang Y, Han Y, Zhao X, Hu H, et al. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. Acta Biomater 2022; 150: 353-66.

[242]

Ma X, Jiang X, Wang Z, Fan Y, Li J, Chow C, et al. Cationic metal-organic layer delivers siRNAs to overcome radioresistance and potentiate cancer radiotherapy. Angew Chem Int Ed Engl 2025; 64: e202419409.

[243]

Jiang Y, Cao H, Deng H, Guan L, Langthasa J, Colburg DRC, et al. Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors. Nat Biotechnol 2024.

[244]

Qi MH, Wang DD, Qian W, Zhang ZL, Ao YW, Li JM, et al. High-efficiency gold nanoaggregates for NIR LED-driven sustained mild photothermal therapy achieving complete tumor eradication and immune enhancement. Adv Mater 2025; 37: 2412191.

[245]

Jia X, Lv M, Fei Y, Dong Q, Wang H, Liu Q, et al. Facile one-step synthesis of NIR-responsive siRNA-inorganic hybrid nanoplatform for imaging-guided photothermal and gene synergistic therapy. Biomaterials 2022; 282: 121404.

[246]

Huang S, Le H, Hong G, Chen G, Zhang F, Lu L, et al. An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy. Acta Biomater 2022; 148: 244-57.

[247]

Cui J, Qin L, Zhang J, Abrahimi P, Li H, Li G, et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells . Nat Commun 2017; 8: 191.

[248]

Brüggenwirth IMA, Martins PN. RNA interference therapeutics in organ transplantation: the dawn of a new era. Am J Transplant 2020; 20: 931-41.

[249]

Buying time for transplants. Nat Biotechnol 2017; 35: 801. doi: 10.1038/nbt.3971.

[250]

Senior M. Beating the organ clock. Nat Biotechnol 2018; 36: 488-92.

[251]

Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers . Nat Commun 2025; 16: 5009.

[252]

Cappelluti MA, Mollica Poeta V, Valsoni S, Quarato P, Merlin S, Merelli I, et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing . Nature 2024; 627: 416-23.

[253]

Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther 2024; 9: 150.

[254]

Li T, Wang Y, Chen X, Cui H, Zhang L, Liu J, et al. Direct cytosolic delivery of siRNA conjugates: a paradigm in antiangiogenic therapy for choroidal neovascularization. ACS Nano 2025; 19: 11249-62.

PDF (7149KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉